Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perfluorocarbon-based oxygen delivery.

Jean G Riess1

  • 1MRI Institute, University of California at San Diego and Alliance Pharmaceutical Corp., San Diego, CA 92103, USA. jriess@allp.com

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
|November 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

About Perfluoropolyhedranes, Their Electron-Accepting Ability and Questionable Supramolecular Hosting Capacity.

Angewandte Chemie (International ed. in English)·2023
Same author

Perfluorocubane-a tiny electron guzzler.

Science (New York, N.Y.)·2022
Same author

Therapeutic oxygen delivery by perfluorocarbon-based colloids.

Advances in colloid and interface science·2021
Same author

Selected physicochemical aspects of poly- and perfluoroalkylated substances relevant to performance, environment and sustainability-part one.

Chemosphere·2014
Same author

Chemistry, physical chemistry, and uses of molecular fluorocarbon--hydrocarbon diblocks, triblocks, and related compounds--unique "apolar" components for self-assembled colloid and interface engineering.

Chemical reviews·2009
Same author

Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery.

Artificial cells, blood substitutes, and immobilization biotechnology·2005
Same journal

The effect of polymerized placenta hemoglobin on renal ischemia/reperfusion injury.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

Immune-stimulating potential of cell envelope proteins from Vibrio cholerae associated to chitosan microparticles: an in vitro study.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

Immobilization of anti-aflatoxin B1 antibody by UV polymerization of aniline and aflatoxin B1 detection via electrochemical impedance spectroscopy.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

Purification and characterization of prophenoloxidase from Galleria mellonella L.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

Chitosan-based intragastric delivery of cefuroxime axetil: development and in-vitro evaluation of mucoadhesive approach.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

In vitro effect of novel β-lactam compounds on xanthine oxidase enzyme activity.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
See all related articles

Perfluorocarbon (PFC) emulsions like Oxygent show promise for oxygen delivery and reducing transfusions. However, adverse events in one trial suggest protocol issues, not emulsion defects.

Area of Science:

  • Biomedical Engineering
  • Anesthesiology
  • Pharmacology

Background:

  • Perfluorocarbons (PFCs) are investigated as oxygen carriers.
  • Developing stable, injectable PFC emulsions is crucial for medical applications.
  • Oxygent is an injectable PFC emulsion developed for oxygen delivery.

Purpose of the Study:

  • Review PFC properties for oxygen delivery.
  • Discuss PFC selection and emulsion engineering.
  • Evaluate Oxygent's clinical efficacy and safety.

Main Methods:

  • Developed Oxygent, a heat-sterilized PFC emulsion (F-octyl bromide, F-decyl bromide, egg phospholipids).
  • Conducted Phase III clinical trials for efficacy and safety.
  • Investigated Oxygent's interaction with cardiopulmonary bypass fluids.

Related Experiment Videos

Main Results:

  • Oxygent demonstrated efficacy in reducing red cell transfusions during surgery.
  • A Phase III trial in cardiopulmonary bypass was halted due to adverse events, attributed to protocol.
  • No adverse effects of Oxygent on hemostasis, hemolysis, or blood rheology were detected.

Conclusions:

  • Oxygent shows potential as an oxygen carrier, reducing transfusion needs.
  • Careful study design is essential when evaluating PFC emulsions in complex procedures.
  • Oxygent appears safe concerning hemostasis, hemolysis, and rheology in bypass contexts.